Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | -2.84% | +10.00% | -25.69% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 25.86M | Capitalization | 81.16M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.14 x |
P/E ratio 2024 * |
-1.41
x | P/E ratio 2025 * |
-2.13
x | Employees | 54 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84% |
Latest transcript on Leap Therapeutics, Inc.
1 day | -3.65% | ||
1 week | +7.09% | ||
Current month | +19.17% | ||
1 month | +32.08% | ||
3 months | +24.80% | ||
6 months | +134.81% | ||
Current year | -23.52% |
Managers | Title | Age | Since |
---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 20-08-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 15-12-31 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 16-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.08 | -2.84% | 208 140 |
24-04-25 | 3.17 | -3.65% | 213,233 |
24-04-24 | 3.29 | +2.81% | 200,614 |
24-04-23 | 3.2 | -0.31% | 89,131 |
24-04-22 | 3.21 | +14.64% | 328,700 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.52% | 81.16M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.41% | 22.02B | |
-17.84% | 20.9B | |
-8.77% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- LPTX Stock